Vertex Sets Sights On Diabetes Cure With $950M Semma Buy
Massachusetts-based Vertex Pharmaceuticals on Tuesday unveiled plans to pay $950 million in cash for Semma Therapeutics, which is developing a treatment that aims to cure Type 1 diabetes. ...To view the full article, register now.
Already a subscriber? Click here to view full article